First Dual-Gene RNA Therapy Cuts LDL Cholesterol by 54% and Triglycerides by 73% in Early Trial

For patients managing complex lipid disorders, standard care typically involves stacking a statin to lower cholesterol alongside a separate medication to control triglycerides—a piecemeal approach that still leaves many at high risk for cardiovascular events. Arrowhead Pharmaceuticals’ newly announced Phase 1/2a trial results for ARO-DIMER-PA diverge from that model entirely by silencing two distinct lipid-driving genes with a single molecule. The dual-functional RNA interference (RNAi) therapeutic reduced low-density lipoprotein cholesterol (LDL-C) by 54% and cut triglycerides by 73% after a single dose, marking the first time a single RNAi candidate has successfully targeted two genes simultaneously in humans.[1][2]

The condition the drug targets, mixed hyperlipidemia, is characterized by dangerous elevations in both LDL-C and triglycerides. While existing therapies like statins and standalone PCSK9 inhibitors are highly effective at clearing LDL-C from the bloodstream, they often fail to adequately address triglyceride-rich lipoproteins. "Mixed hyperlipidemia is not adequately addressed by treating LDL-C alone," noted Dr. Steven Nissen, chief academic officer for the Heart and Vascular Institute at the Cleveland Clinic. "Even with intensive statin therapy and PCSK9 inhibitors, substantial ASCVD risk remains, and triglyceride-rich remnant lipoproteins may be an important part of that residual risk."[3]

To bridge that gap, ARO-DIMER-PA utilizes Arrowhead’s proprietary Targeted RNAi Molecule (TRiM) platform to deliver a dual-action payload directly to the liver. The therapeutic is designed to halt the production of two specific proteins: proprotein convertase subtilisin/kexin type 9 (PCSK9) and apolipoprotein C-III (APOC3). PCSK9 normally degrades the receptors that clear LDL cholesterol from the blood, while APOC3 inhibits the breakdown of triglycerides. By silencing the genes responsible for both proteins simultaneously, the drug effectively removes the biological brakes on the body's natural lipid-clearing machinery.[2][3]

The interim data released on September 15, 2026, emerged from the single-dose escalation portion of the ARO-DIMER-PA-1001 trial, which enrolled up to 78 adult subjects. Researchers tested single ascending doses up to 400 milligrams. The biomarker results demonstrated deep and durable gene silencing: participants experienced a dose-dependent mean maximal reduction in serum PCSK9 of 72%, alongside an 88% mean maximal reduction in APOC3.[2][4]

Those genetic knockdowns translated directly into broad lipid improvements. Beyond the 54% drop in LDL-C and the 73% reduction in triglycerides, the single-dose regimen also drove a 61% reduction in non-high-density lipoprotein (non-HDL) cholesterol. Furthermore, levels of Apolipoprotein B (ApoB)—a structural protein found on all atherogenic particles and considered one of the most accurate markers of cardiovascular risk—fell by 50%.[1][4]

Safety data from this early-stage cohort appeared reassuring, though the sample size remains small. The most commonly reported treatment-emergent adverse events were mild injection site reactions and headaches. Arrowhead confirmed that no drug-related serious adverse events have been reported to date. The trial is now advancing to its second phase, which will evaluate the safety, tolerability, and pharmacodynamics of multiple-dose regimens over a longer duration.[2][4]

For patients currently managing mixed hyperlipidemia, these results offer a glimpse into the future of cardiovascular care, but they do not alter immediate treatment protocols. ARO-DIMER-PA is still years away from potential regulatory approval, and patients should strictly maintain their current statin and lipid-lowering regimens. The true test for the drug will be whether these profound lipid reductions can be safely maintained over years of repeat dosing, and ultimately, whether they translate into fewer heart attacks and strokes in massive Phase 3 cardiovascular outcomes trials.[3][5]

Beyond cardiovascular disease, the trial represents a major technical milestone for the broader field of genetic medicine. "With these interim topline results, Arrowhead's innovative and proprietary Targeted RNAi Molecule (TRiM) platform has achieved clinical validation of its ability to target and silence two genes simultaneously in one molecule," said Arrowhead President and CEO Chris Anzalone. If the dual-targeting approach proves safe in larger cohorts, the same molecular architecture could theoretically be adapted to treat a wide range of complex polygenic diseases that currently require multiple overlapping medications.[2]